(Q33212324)

24 July 2017

Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants (English)

1 reference

24 July 2017

0 references

Inge Berthold

1

1 reference

24 July 2017

Maria-Luz Pombo

series ordinal

2

1 reference

24 July 2017

Leslie Wagner

series ordinal

3

1 reference

24 July 2017

Juan L Arciniega

series ordinal

4

1 reference

24 July 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

24 July 2017

1 reference

24 July 2017

23

1 reference

24 July 2017

16

1 reference

24 July 2017

1993-1999

1 reference

Biodefense R&D: anticipating future threats, establishing a strategic environment

24 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.014

Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.014

Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.014

Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.014

In vitro correlate of immunity in a rabbit model of inhalational anthrax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.014

Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.014

Aluminum salts in vaccines--US perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.014

In vivo absorption of aluminium-containing vaccine adjuvants using 26Al.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.014

Production and purification of anthrax toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.014

Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.014

Validation of the anthrax lethal toxin neutralization assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.014

Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.014

Predicting the adsorption of proteins by aluminium-containing adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.014

Bioterrorism preparedness and response: clinicians and public health agencies as essential partners

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.014

Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.014

Mechanisms of stimulation of the immune response by aluminum adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.014

Neurological adverse events associated with vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.014

Effect of aluminum adjuvants on safety and immunogenicity of Haemophilus influenzae type b-CRM197 conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.014

Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.014

10.1016/J.VACCINE.2004.10.014

7 January 2021

Identifiers

DOI

1 reference

24 July 2017

1 reference